BioGaia has signed a new agreement with the Swiss biopharmaceutical company Ferring Pharmaceuticals. The agreement gives Ferring exclusive rights to sell BioGaia´s Probiotic Drops in Australia, New Zealand and Israel as well as BioGaia´s Probiotic Tablets in Brazil, Egypt, Greece, Iran, Jordan, Canada, Lebanon, Mexico, Saudi Arabia and Syria.
The collaboration, which was first initiated in spring 2006, has been so successful that, as well as extending the duration of the agreement, Ferring will be marketing BioGaia's Probiotic Drops in additional markets and adding a tablet form of the treatment to its product portfolio.
The drops have already been launched in Spain, Portugal, The Czech Republic and Canada and it is expected that they will be launched in Jordan and Mexico during the first quarter 2008. Ferring has further exclusive rights to sell BioGaia's Probiotic Drops in Brazil, Egypt, Greece, Iran, Lebanon, Saudi Arabia and Syria.
"We are very pleased with the success of our collaboration with BioGaia. BioGaia's Probiotic Drops have been very well-received by the medical profession and the patients and we are delighted to be able to make it available to more patients globally and to add a new administration form, which some patients will find more convenient." says Michel Pettigrew, COO at Ferring
The agreement means that BioGaia´s brand will be found in a large number of new markets and this is a stepping stone in our efforts to create a global brand for probiotic dietary supplements." says Peter Rothschild, President, BioGaia AB.
Ferring is a Swiss-based research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology. In recent years Ferring has expanded beyond its traditional European base and has offices in over 40 countries. To learn more about Ferring or its products please visit www.ferring.com.
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm.